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Dear Editor:
Solitary extramedullary plasmocytoma (SEP) is an exceeding-
ly rare entity accounting for less than 5 % of all plasma cell
dyscrasias, such as monoclonal gammopathy of undetermined
significance (MGUS), multiple myeloma (MM), solitary
plasmocytoma of the bone, and monoclonal immunoglobulin
deposition diseases. SEP is usually found in the upper respi-
ratory tract and secondary in the gastrointestinal tract, with
only 6.2 % arising in the large bowel [1]. Only fifteen case of
ano-rectal SEP were reported in the English literature.
The diagnosis of SEP requires demonstration of a mono-
clonal plasma cell infiltration in organs other than the bone
marrow without evidence of systemic involvement [2].
SEP patients mainly manifest with local masses and rele-
vant symptoms, which are nonspecific and depend on the site
and spread of the tumor. In the low GI tract, obstruction, rectal
bleeding, and abdominal pain were more commonly
described.
Among plasma cell neoplasia, SEP shows the best progno-
sis with 10-year overall survival rate of 70 %. Although a
transformation into MM has been described in a small per-
centage of case (∼15 %), patients with SEP that progressed to
MM had a 100 % 5-year survival rate [3].
We reported a case of rectal SEP in a 60-years-old man
presented with a 1 month of history of painless hematochezia
and diarrhea. Past medical and surgical history of ischemic
heart disease and femur fracture was reported.
At physical examination, no palpable abdominal or rectal
mass were detected.
Colonoscopy revealed one small polyp in the cecum and
three polyps in the rectum, two small and one of large size.
Endoscopic mucosal resection (EMR) was performed for the
largest.
At macroscopic examination, the large rectal polyp, of 4×
3×2.5 cm of size, showed a smooth surface superficially
ulcerated. The surgical margin was inked in black. At section,
the specimen showed a fleshy and multicystic appearance and
was involved in toto. All sections were processed for histo-
logical analysis.
The three small size polyps were tubulo adenoma with low
grade dysplasia.
Histological analysis of the largest polyp showed massive
infiltration by medium-sized cells, characterized by abundant
pale to eosinophilic cytoplasm and eccentric nuclei with a
cartwheel arrangement of the chromatin. Neither mitosis nor
apoptotic figures were found. No residual rectal glands were
found. Congo red staining showed no amyloid deposits.
At immunohistochemistry, tumor cells revealed diffuse
reactivity for CD138 and for immunoglobulin kappa light
chains. Immunostaining for lambda light chains, CD20,
CD45 were negative on tumoral cells. Ki67 showed a low
proliferation rate. Immunostaining for CD3 revealed some
accompanying T cells CD3+.
A diagnosis of rectal plasmocytoma was retained.
As rectal plasmocytomas are extremely rare, reactive
plasmacytosis, plasma cell granuloma, and lymphoma with
plasma cell differentiation (mucosa-associated lymphoid tis-
sue (MALT), lymphoblastic, and immunoblastic) have to be
excluded in order to avoid misdiagnosis.
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The most challenging differential diagnosis is between a
plasmocytoma and a MALT lymphoma with marked plasma
cell differentiation, as they may have a similar histological
appearance.
In MALT lymphoma, the neoplastic infiltrate is composed
of B lymphocytes and plasma cells. In our case, the absence of
a small B lymphocyte infiltrate and the absence of expression
of CD20 by the plasmocytic cell lead us to rule out the
diagnosis of a an indolent B lymphoma with marked plasma
cell differentiation.
A reactive plasmacytosis and a plasma cell granuloma have
been excluded as they originated from polyclonal plasma cells
and in our case a restriction for the immunoglobulin kappa
light chains was observed.
We also excluded more aggressive lymphoma showing
differentiation into immature plasma cells (lymphoblastic
and immunoblastic) as no significant atypia or high prolifer-
ation index were observed in our case.
Further investigations were made to determine whether the
tumor was solitary or a localization of a multiple myeloma.
MRI showed neither bone lesions suspicious for medullary
replacement nor lytic lesions. Laboratory tests showed no
monoclonal gammaglobulin peak, nor LDH and β2-
microglobulin elevation. Renal function and calcemia were
normal. No proteinuria was found. The κ/λ ratio was normal.
At 8 months of follow-up, the patient is asymptomatic and
colonoscopy revealed no recurrence.
SEP shows an indolent clinical behavior. The 10-year
overall survival rate is 70 % in SEP. Approximately 65 % of
the patients had no recurrence and did not progress to MM [4]
Only 15 % of the SEP seems to progress to MM compared to
solitary bone plasmocytoma (SBP) with a significantly higher
risk of progression to MM. Moreover, patients with SEP
evolved into MM had a 100 % 5-year survival rate as com-
pared to 33 % for SBP.
Due to the rarity and the scattered reports of SEP, determi-
nation of the prognostic factors can be difficult. Large tumor
size (>5 cm) and elevated β2 microglobulin (>3.5 mg/L)
seems to be adverse factors, affecting survival. Radiotherapy
and serum β2 microglobulin <3.5 mg/L were favorable prog-
nostic factors for local control, multiple myeloma-free surviv-
al, and progression-free survival in patients with SEP [3].
In our case, the tumor size was less than 5 cm and the β2
microglobulin was not elevated (<3.5 mg/L). Radiotherapy
was not performed as a complete surgical resection was
achieved.
For SEP in GI tract treated with primary surgery, RT will
only be required in case of inadequate surgical margins.
Combined therapy is also recommended if complete surgical
tumor resection is unfeasible or impossible and/or lymph node
areas are affected and/or the patient is high risk to progress to
MM. No beneficial effect of adjuvant chemotherapy on dis-
ease control or prevention of progression to multiple myeloma
has been reported by several authors [3].
Despite this tumor presents a good prognosis, a long-term
follow-up is recommended as in a minority of cases, SEP may
progress into the more aggressive MM.
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